<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>.03 Selecting Drugs for Cost Review. | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/14.01/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/14.01/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|14|01|04|.03|"/>
    <meta itemprop="doc-type" content="section" data-document=""/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="14|01|04|.03" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="http://regs.maryland.gov//us/md/exec/comar/14.01.04.03"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content=".03 Selecting Drugs for Cost Review. | Library of Maryland Regulations"/>
    <meta property="og:image" content="http://regs.maryland.gov//us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/14.01/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/14.01/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14" data-search-heading="">
                  <a href="/us/md/exec/comar/14" title="Title 14 INDEPENDENT AGENCIES">Title 14 INDEPENDENT AGENCIES</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14|01" data-search-heading="">
                  <a href="/us/md/exec/comar/14.01" title="Subtitle 01 PRESCRIPTION DRUG AFFORDABILITY BOARD">Subtitle 01 PRESCRIPTION DRUG AFFORDABILITY BOARD</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14|01|04" data-search-heading="">
                  <a href="/us/md/exec/comar/14.01.04" title="Chapter 04 Cost Review Study Process">Chapter 04 Cost Review Study Process</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14|01|04|.03" data-search-heading="">
                  <span title=".03 Selecting Drugs for Cost Review.">.03 Selecting Drugs for Cost Review.</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="14|01|04|.03">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/md/exec/comar/14.01.04.03">.03 Selecting Drugs for Cost Review.</h1>
                <p class="text-indent-1 "><span class="level-num" id="A">A.</span> Board staff may provide the Board with a dashboard containing the prescription drug products identified under the statutory metrics and regulatory criteria in <a class="internal-link " href="/us/md/exec/comar/14.01.04.02" title=".02 Identifying Drugs Eligible for Cost Review.">Regulation .02 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="B">B.</span> To the extent practicable, Board staff may provide the following information for each prescription drug product in the dashboard:</p>
                <p class="text-indent-2 "><span class="level-num" id="B(1)">(1)</span> FDA Approval:</p>
                <p class="text-indent-3 "><span class="level-num" id="B(1)(a)">(a)</span> The date the FDA first approved the prescription drug product;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(1)(b)">(b)</span> If applicable, the date the last patent expired or will expire;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(1)(c)">(c)</span> Whether the prescription drug product was approved through an FDA accelerated approval pathway; and</p>
                <p class="text-indent-3 "><span class="level-num" id="B(1)(d)">(d)</span> Whether the prescription drug product is designated by the Secretary of the FDA, under 21 U.S.C. §360bb, as a drug for a rare disease or condition;</p>
                <p class="text-indent-2 "><span class="level-num" id="B(2)">(2)</span> Therapeutic Class:</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(a)">(a)</span> The class of the prescription drug product as identified in a recognized classification system;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(b)">(b)</span> Whether the prescription drug product is the only prescription drug product in its class;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(c)">(c)</span> Any therapeutic equivalent prescription drug product identified by examination of the FDA Orange Book, FDA Purple Book, or other therapeutic equivalence databases; and</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(d)">(d)</span> The availability and number of therapeutic equivalents for sale in the State;</p>
                <p class="text-indent-2 "><span class="level-num" id="B(3)">(3)</span> Utilization, Spending and Price Data:</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(a)">(a)</span> The patient count for the prescription drug product in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(b)">(b)</span> The total gross spending for the prescription drug product in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(c)">(c)</span> The total gross spending per patient for the prescription drug product in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(d)">(d)</span> The WAC on January 1 of the current calendar year, on January 1 of the previous calendar year, and at launch of the product;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(e)">(e)</span> The percent increase in WAC of the prescription drug product over the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(f)">(f)</span> The percent increase in WAC of the prescription drug product over the most recent available 5-year period;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(g)">(g)</span> The dollar increase in WAC over the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(h)">(h)</span> The dollar increase in WAC over the most recent available 5-year period;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(i)">(i)</span> The dollar increase in WAC per year or course of treatment over the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(j)">(j)</span> The percent increase in overall total gross spending for the prescription drug product in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(k)">(k)</span> The estimated percentage of manufacturer national net sales to gross sales of a prescription drug product for the most recently reported year;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(l)">(l)</span> The average payor cost per patient for the prescription drug product in the most recent available calendar year; and</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(m)">(m)</span> The average cost share for the prescription drug product;</p>
                <p class="text-indent-2 "><span class="level-num" id="B(4)">(4)</span> Patient Out-of-Pocket:</p>
                <p class="text-indent-3 "><span class="level-num" id="B(4)(a)">(a)</span> The total patient out-of-pocket cost for the prescription drug product in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(4)(b)">(b)</span> The average total out-of-pocket costs in the most recent available calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(4)(c)">(c)</span> Patient total out-of-pocket costs ranked at the 50th percentile in the most recent available calendar year; and</p>
                <p class="text-indent-3 "><span class="level-num" id="B(4)(d)">(d)</span> Patient total out-of-pocket costs ranked at the 90th percentile in the most recent available calendar year;</p>
                <p class="text-indent-2 "><span class="level-num" id="B(5)">(5)</span> Whether the prescription drug product is currently in active shortage status; and</p>
                <p class="text-indent-2 "><span class="level-num" id="B(6)">(6)</span> Whether the prescription drug product is currently subject to or has been subject to the Medicare Drug Price Negotiation Program, under the Inflation Reduction Act (IRA) (Public Law 117-169).</p>
                <p class="text-indent-1 "><span class="level-num" id="C">C.</span> Selecting Drugs for Referral to Stakeholder Council.</p>
                <p class="text-indent-2 "><span class="level-num" id="C(1)">(1)</span> The Board may select one or more prescription drug products identified in <a class="internal-link " href="/us/md/exec/comar/14.01.04.02" title=".02 Identifying Drugs Eligible for Cost Review.">Regulation .02 of this chapter</a> as eligible for cost review to refer to the Stakeholder Council.</p>
                <p class="text-indent-2 "><span class="level-num" id="C(2)">(2)</span> Prior to a Board meeting, a Board member may request that a prescription drug product or products be placed on the Board’s meeting agenda for consideration for referral to the Stakeholder Council by submitting the proprietary drug name or nonproprietary name, as applicable, and NDC to the Board Chair in writing.</p>
                <p class="text-indent-2 "><span class="level-num" id="C(3)">(3)</span> The Board Chair may include the prescription drug product name and dose on the Board’s agenda.</p>
                <p class="text-indent-2 "><span class="level-num" id="C(4)">(4)</span> The public may provide oral and written comments concerning the drugs proposed for referral to the Stakeholder Council and identified on the meeting agenda in accordance with the procedures and timelines in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#A" title="">COMAR 14.01.01.05A</a> and B(2).</p>
                <p class="text-indent-2 "><span class="level-num" id="C(5)">(5)</span> Notwithstanding the pre-meeting identification of drugs for consideration, the Board may consider any drug identified in <a class="internal-link " href="/us/md/exec/comar/14.01.04.02" title=".02 Identifying Drugs Eligible for Cost Review.">Regulation .02 of this chapter</a> for referral to the Stakeholder Council.</p>
                <p class="text-indent-2 "><span class="level-num" id="C(6)">(6)</span> At an open meeting, the Board may:</p>
                <p class="text-indent-3 "><span class="level-num" id="C(6)(a)">(a)</span> Consider the prescription drug products identified on the Board’s agenda and any eligible drug proposed for consideration by a Board member at the meeting; and</p>
                <p class="text-indent-3 "><span class="level-num" id="C(6)(b)">(b)</span> Select one or more prescription drug products by NDC to refer to the Stakeholder Council to receive input from the Stakeholder Council on the selection of prescription drug products for cost review.</p>
                <p class="text-indent-1 "><span class="level-num" id="D">D.</span> In selecting one or more prescription drug products to refer to the Stakeholder Council, the Board may consider:</p>
                <p class="text-indent-2 "><span class="level-num" id="D(1)">(1)</span> The prescription drug products identified under the statutory metrics and regulatory criteria in <a class="internal-link " href="/us/md/exec/comar/14.01.04.02" title=".02 Identifying Drugs Eligible for Cost Review.">Regulation .02 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="D(2)">(2)</span> The information provided under §B this regulation;</p>
                <p class="text-indent-2 "><span class="level-num" id="D(3)">(3)</span> The average cost share of the prescription drug product, the average patient total out-of-pocket cost, and the average total payor cost; and</p>
                <p class="text-indent-2 "><span class="level-num" id="D(4)">(4)</span> Any written or oral public comment.</p>
                <p class="text-indent-1 "><span class="level-num" id="E">E.</span> The Board shall post notice of the prescription drug products referred to the Stakeholder Council on its website.</p>
                <p class="text-indent-1 "><span class="level-num" id="F">F.</span> The public may provide written comments concerning the list of prescription drug products referred to the Stakeholder Council by:</p>
                <p class="text-indent-2 "><span class="level-num" id="F(1)">(1)</span> Complying with the procedures in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#B(3)" title="">COMAR 14.01.01.05B(3)</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="F(2)">(2)</span> Submitting the written comments to the Board within 30 calendar days of the date the list is posted on the Board’s website.</p>
                <p class="text-indent-1 "><span class="level-num" id="G">G.</span> Stakeholder Council Input.</p>
                <p class="text-indent-2 "><span class="level-num" id="G(1)">(1)</span> To the extent practicable, the Board may provide the Stakeholder Council with:</p>
                <p class="text-indent-3 "><span class="level-num" id="G(1)(a)">(a)</span> The information set forth in <a class="internal-link " href="/us/md/exec/comar/14.01.04.03#B" title="">§B of this regulation</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="G(1)(b)">(b)</span> Whether the prescription drug product was reported by an individual member of the public; and</p>
                <p class="text-indent-3 "><span class="level-num" id="G(1)(c)">(c)</span> Whether the prescription drug product was added by the Board for consideration under <a class="internal-link " href="/us/md/exec/comar/14.01.04.02" title=".02 Identifying Drugs Eligible for Cost Review.">Regulation .02 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="G(2)">(2)</span> To the extent practicable, the Stakeholder Council shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="G(2)(a)">(a)</span> Review the information provided for each referred prescription drug product; and</p>
                <p class="text-indent-3 "><span class="level-num" id="G(2)(b)">(b)</span> Discuss the referred prescription drug products at an open meeting.</p>
                <p class="text-indent-2 "><span class="level-num" id="G(3)">(3)</span> Board staff may present the Stakeholder Council input discussed at the open meeting to the Board.</p>
                <p class="text-indent-1 "><span class="level-num" id="H">H.</span> Therapeutic Alternatives.</p>
                <p class="text-indent-2 "><span class="level-num" id="H(1)">(1)</span> Board staff may develop a list of therapeutic alternatives for each prescription drug product referred to the Stakeholder Council.</p>
                <p class="text-indent-2 "><span class="level-num" id="H(2)">(2)</span> Board staff shall post a list of therapeutic alternatives developed by staff on the Board’s website for comment.</p>
                <p class="text-indent-2 "><span class="level-num" id="H(3)">(3)</span> The public may provide written comments concerning the list of therapeutic alternatives by:</p>
                <p class="text-indent-3 "><span class="level-num" id="H(3)(a)">(a)</span> Complying with the procedures in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#B(3)" title="">COMAR 14.01.01.05B(3)</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="H(3)(b)">(b)</span> Submitting the written comments to the Board within 30 calendar days of the date the list is posted on the Board’s website.</p>
                <p class="text-indent-2 "><span class="level-num" id="H(4)">(4)</span> Board staff may modify the list of therapeutic alternatives for consideration by the Board.</p>
                <p class="text-indent-2 "><span class="level-num" id="H(5)">(5)</span> The Board shall determine the therapeutic alternatives for each prescription drug product selected for a cost review study.</p>
                <p class="text-indent-1 "><span class="level-num" id="I">I.</span> Board Selection of Drugs for Cost Review.</p>
                <p class="text-indent-2 "><span class="level-num" id="I(1)">(1)</span> At an open meeting, the Board may select one or more prescription drug products for a cost review study.</p>
                <p class="text-indent-2 "><span class="level-num" id="I(2)">(2)</span> The public may provide oral and written comments concerning the selection of a prescription drug product for cost review in accordance with the procedures and timelines in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#A" title="">COMAR 14.01.01.05A</a> and B(2).</p>
                <p class="text-indent-2 "><span class="level-num" id="I(3)">(3)</span> In selecting a prescription drug product for cost review, the Board shall consider:</p>
                <p class="text-indent-3 "><span class="level-num" id="I(3)(a)">(a)</span> The prescription drug products referred to the Stakeholder Council from the prescription drug products identified under the statutory metrics and regulatory criteria in <a class="internal-link " href="/us/md/exec/comar/14.01.04.02" title=".02 Identifying Drugs Eligible for Cost Review.">Regulation .02 of this chapter</a> and the information provided under <a class="internal-link " href="/us/md/exec/comar/14.01.04.03#B" title="">§B of this regulation</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="I(3)(b)">(b)</span> The average cost share of the prescription drug product, the average patient total out-of-pocket cost, the average total payor cost, and publicly available data on direct-to-consumer advertising spending for the prescription drug product;</p>
                <p class="text-indent-3 "><span class="level-num" id="I(3)(c)">(c)</span> Input from the Stakeholder Council provided under <a class="internal-link " href="/us/md/exec/comar/14.01.04.03#G" title="">§G of this regulation</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="I(3)(d)">(d)</span> Input from the public provided under <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05" title=".05 Public Comment Procedures.">COMAR 14.01.01.05</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="I(4)">(4)</span> During an open meeting, the Board may select one or more prescription drug products for cost review under <a class="internal-link " href="/us/md/exec/comar/14.01.04.05" title=".05 Cost Review Study.">Regulation .05 of this chapter</a> and provide notice of the selection on its website within 3 work days of the meeting.</p>
                <p class="text-indent-2 "><span class="level-num" id="I(5)">(5)</span> The prescription drug product shall be identified by:</p>
                <p class="text-indent-3 "><span class="level-num" id="I(5)(a)">(a)</span> NDC;</p>
                <p class="text-indent-3 "><span class="level-num" id="I(5)(b)">(b)</span> ANDA, NDA, or BLA, as applicable; and</p>
                <p class="text-indent-3 "><span class="level-num" id="I(5)(c)">(c)</span> Active moiety or active ingredient.</p>
                <p class="text-indent-2 "><span class="level-num" id="I(6)">(6)</span> If the Board selects a prescription drug product for cost review, the Board may identify and approve all NDCs marketed under the same ANDA, NDA, or BLA to be included in the cost review.</p>
                <p class="text-indent-2 "><span class="level-num" id="I(7)">(7)</span> If the Board selects a prescription drug product for cost review that is an unapproved generic within the meaning of Health-General Article, §21-2C-01(f), Annotated Code of Maryland, the Board may identify and approve all NDCs with the same active moiety and manufacturer to be included in the cost review study.</p>
                <p class="text-indent-2 "><span class="level-num" id="I(8)">(8)</span> If the Board selects a prescription drug product for cost review, the Board shall approve the therapeutic alternatives to be used in conducting the cost review study.</p>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/14.01.04.02" aria-label=".02 Identifying Drugs Eligible for Cost Review.">
                <div class="h__ui">Previous</div>
                <span>.02 Identifying Drugs Eligible for Cost Review.</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/14.01.04.04" aria-label=".04 Request for Information for Cost Review.">
                <div class="h__ui">Next</div>
                <span>.04 Request for Information for Cost Review.</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
<p>This version of the laws and codes on this website is licensed under the <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/">CC BY-NC-SA 4.0</a> license with copyright held by the State of Maryland.</p><p>This version of the laws and codes on this website will be dedicated to the public domain under the <a href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0</a> license 180 days after publication.</p>
<p>
      Please do not scrape. Instead, bulk download the CC BY-NC-SA-4.0 <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a> or CC0 <a href="https://github.com/maryland-dsd/law-html-cc0">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml-cc0">XML</a>.
    </p><p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p></div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
